Pakistan
BF Biosciences Limited, a leading biopharmaceutical company, has announced the launch of its innovative product Zeptide® (Tirzepatide) in an easy-to-use pre-filled syringe format, marking a major step forward in the fight against diabetes and obesity in Pakistan.
In a disclosure to the Pakistan Stock Exchange (PSX) under Sections 96 and 131 of the Securities Act, 2015 and Clause 5.6.1(a) of the PSX Rule Book, the company said Tirzepatide is a synthetic polypeptide that acts as a dual agonist for the GLP-1 and GIP receptors, targeting key pathways for blood sugar and metabolic control. The drug is approved by the US Food and Drug Administration (FDA) for treating Type 2 diabetes mellitus (T2DM) and obesity.
Zeptide® is produced at BF Biosciences’ state-of-the-art European prefilled syringe facility. The pre-filled format aims to enhance patient safety and convenience by reducing dosing errors. The product’s quality, structure, and potency have been verified by a leading biological mass spectrometry laboratory in the US and a national university in Pakistan.
The company noted that Pakistan has one of the highest diabetes prevalence rates globally, with 9 million undiagnosed patients and alarming rates of overweight and obesity—affecting 57% of women and 41% of men, according to the World Health Organization (WHO).
As Pakistan’s first biopharmaceutical plant, BF Biosciences has been producing essential medicines for HCV, cancer, cardiology, diabetes, nephrology, and other therapeutic areas for over a decade. The company said the launch of Zeptide® represents an important milestone in its mission to address critical unmet medical needs and is expected to positively impact future growth. – ER News Desk
More on Healthcare
